PARTNERSHIP PATHWAYS · GCC & INTERNATIONAL
Partnership withContinuum Innovative.
Continuum Innovative is a hair-loss biology innovation platform: proprietary science, a patent-pending IP portfolio, peer-reviewed evidence, and a commercialization record that has already been proven in the Gulf. We do not sell direct-to-consumer at scale. We work through partners — distributors, pharmacy groups, licensees, co-development partners and strategic investors — who can take validated technology into a market they already own.
This page sets out exactly which relationships are available, what we bring, what we ask of a partner, and how a serious conversation begins.
6
PATENT-PENDING IP PROGRAMS
25+
YEARS OF GCC DISTRIBUTION
5
PEER-REVIEWED PUBLICATIONS
25
COUNTRIES REACHED COMMERCIALLY
WHAT WE ARE
A licensing and commercialization counterparty.
Continuum Innovative integrates discovery science, translational development, intellectual property, clinical validation and commercialization within a coordinated life-sciences platform. Our objective is to translate differentiated human biology into proprietary, commercially deployable technologies — and to selectively partner with organizations capable of accelerating their development, validation and global commercialization.
For a commercial decision-maker, the practical translation is this: the science is already done, the intellectual property is already filed, the formulations already exist, and the products have already been sold through Gulf pharmacy retail. What we are looking for is the counterparty who can put them in front of the right market.
Distribution partnership
Exclusive or market-specific distribution of HairGenesis® and TrichoCyte™ for pharmacy chains, wholesalers and retail groups. GCC distribution opportunities.
Technology licensing
Licensing of formulations, delivery technology and patent-pending programs into a partner's own brand, category or territory. Licensing terms and structures.
Co-development
Joint development of a formulation or product line against a defined commercial specification, using Continuum's mechanism and delivery work as the scientific foundation.
Strategic investment
Capital partnership with strategic value — market access, manufacturing, regulatory capability or channel control. Strategic investment.
Commercialization partnership
Structured programs where a partner leads market execution and Continuum supplies the scientific, technical and documentation substance behind it.
Scientific advisory
Independent evaluation of a third-party technology before you license or invest. Strategic Scientific Advisory.
WHY THIS IS UNUSUAL
Most inbound science has never been sold. Ours has.
The hardest part of a licensing decision is rarely the mechanism. It is whether the asset survives contact with a real market — regulatory documentation, formulation stability, pharmacist acceptance, repeat purchase, and a claim set that does not collapse under scrutiny.
Continuum's portfolio has already been through that. HairGenesis® reached commercial distribution in twenty-five countries and, at peak, was the leading dermatologist-recommended nano-enabled hair growth system, with more than $100M in lifetime revenue across its commercial life. In the Gulf specifically, the platform's products have been carried for more than twenty-five years through Boots Middle East, Aster Pharmacy, Life Pharmacy and Bin Sina Pharmacy.
- Mechanism — botanical 5α-reductase inhibition and anti-inflammatory follicular signaling, published in peer-reviewed journals.
- Delivery — TrichoCyte™ pairs actives with a β-cyclodextrin inclusion complex rather than relying on the active alone.
- Evidence — five peer-reviewed publications, including a randomized, double-blind, placebo-controlled trial.
- IP — a six-program provisional patent portfolio covering the current generation of programs.
WHAT WE ASK OF A PARTNER
Selective, not opportunistic.
We are not looking for the largest number of partners. We are looking for the few organizations for whom this portfolio is genuinely strategic — because they already control shelf space, a physician network, a registration pathway, or a category position that the technology can be dropped into.
Category ownership
You already sell into pharmacy, derma-cosmetic, aesthetic or wellness channels in your market.
Regulatory capability
You hold, or can obtain, the registrations required in your territory and you own that process.
Commercial seriousness
You can articulate volume expectations, channel plan and launch timing rather than requesting samples.
Scientific literacy
You are prepared to evaluate mechanism, delivery and evidence — not just packaging and margin.
HOW A CONVERSATION BEGINS
Three steps, no ceremony.
1 — You tell us the market and the channel.
2 — We send the scientific and commercial package.
3 — We discuss structure.
EXPLORE THE PARTNERSHIP ARCHITECTURE
NEXT STEP
Tell us your market and your channel.
One message is enough to start: the territory, the channel you control, and what you currently sell there. Inquiries are read by Dr. Geno Marcovici, founder and principal investigator.
OPEN A PARTNERSHIP CONVERSATION